期刊
CELL REPORTS
卷 16, 期 6, 页码 1614-1628出版社
CELL PRESS
DOI: 10.1016/j.celrep.2016.07.009
关键词
-
类别
资金
- American Cancer Society [13-068-01-TBG]
- CDMRP LCRP grant [LC110229]
- CPRIT [RP140672, RP140110, RP101496, RP120732, RP110709]
- NCI [5P50 CA70907-15, R01 CA157996-01]
- UT Southwestern Friends of the Comprehensive Cancer Center
- Gibson Foundation
- Texas 4000
- Welch Foundation research grant [I-1733]
- Lung Cancer SPORE [P50CA70907]
- NIH [K01GM109317]
- Harold C. Simmons Comprehensive Cancer Center through NCI Cancer Center support grant [1P30 CA 142543-01]
- MD Anderson's Institutional Tissue Bank [2P30CA016672]
- NIH National Cancer Institute
KRAS is one of the most commonly mutated oncogenes in human cancer. Mutant KRAS aberrantly regulates metabolic networks. However, the contribution of cellular metabolism to mutant KRAS tumorigenesis is not completely understood. We report that mutant KRAS regulates intracellular fatty acid metabolism through Acyl-coenzyme A (CoA) synthetase long-chain family member 3 (ACSL3), which converts fatty acids into fatty Acyl-CoA esters, the substrates for lipid synthesis and beta-oxidation. ACSL3 suppression is associated with depletion of cellular ATP and causes the death of lung cancer cells. Furthermore, mutant KRAS promotes the cellular uptake, retention, accumulation, and beta-oxidation of fatty acids in lung cancer cells in an ACSL3-dependent manner. Finally, ACSL3 is essential for mutant KRAS lung cancer tumorigenesis in vivo and is highly expressed in human lung cancer. Our data demonstrate that mutant KRAS reprograms lipid homeostasis, establishing a metabolic requirement that could be exploited for therapeutic gain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据